Premium Brand STROMUSC Drostanolone Propionate 100mg/ml For Bodybuilding CAS:58-19-5

    Introduction

    Drostanolone propionate occupies a peculiar position within the landscape of performance-enhancing compounds. Unlike testosterone or nandrolone, which are widely recognized even outside athletic circles, drostanolone remains relatively obscure to the general public yet commands significant attention among physique athletes and competitive bodybuilders. Marketed under trade names such as Masteron, Drolban, and Masteril, this compound represents a fascinating intersection of pharmaceutical history and contemporary bodybuilding practice.

    The 100mg/ml concentration is particularly significant in the context of bodybuilding applications. This specific formulation has become a standard in the underground laboratory market, offering practitioners a convenient dosing framework that aligns with the compound's relatively short active window. Understanding drostanolone propionate requires examining it not merely as an anabolic steroid, but as a specialized tool with distinct pharmacological properties that differentiate it from the broader category of androgenic compounds.

    Drostanolone propionate is a synthetic anabolic-androgenic steroid derived from dihydrotestosterone (DHT). The chemical designation 2α-methyl-4,5α-dihydrotestosterone-17β-propionate reveals its structural lineage: it is essentially DHT that has undergone two key modifications. The first involves the addition of a methyl group at the carbon-2 alpha position, while the second is the esterification of the 17-beta hydroxyl group with propionic acid.

    The methyl group at carbon-2 serves a critical pharmacological purpose. It protects the hormone from metabolic breakdown by the 3-hydroxysteroid dehydrogenase enzyme found in skeletal muscle tissue. This enzymatic protection significantly enhances the compound's anabolic potency compared to unmodified DHT, which is rapidly degraded in muscle tissue before it can exert meaningful anabolic effects.

    The propionate ester attached at the 17-beta position governs the compound's release kinetics. Esterified steroids are less polar than their free counterparts, which means they are absorbed more slowly from the injection site. Once in the bloodstream, plasma esterases cleave the propionate ester to liberate the active drostanolone molecule. This esterification strategy extends the therapeutic window following administration, permitting a less frequent injection schedule than would be required with unesterified drostanolone.

    It is worth noting that drostanolone was originally developed as an antineoplastic agent for the treatment of breast carcinoma. Its clinical utility in this context stemmed from its ability to inhibit the uptake of oestradiol-17β by tumor tissue without affecting normal breast tissue. While this oncological application has largely fallen out of favor, it provides important context for understanding the compound's anti-estrogenic properties, which later became highly relevant in bodybuilding contexts.

    The defining characteristic of drostanolone is its relationship with estrogen. As a DHT derivative, drostanolone cannot be converted into estrogenic metabolites because it is not a substrate for the aromatase enzyme. This fundamental distinction separates it from testosterone, nandrolone, and other aromatizable compounds that require careful management of estrogenic side effects.

    Beyond simply lacking estrogenic activity, drostanolone appears to possess direct anti-estrogenic properties. Research suggests it may compete with estrogen for binding to the aromatase enzyme, effectively reducing estrogen production from other compounds in a stack. This dual action-being inherently non-estrogenic while actively opposing estrogen-has made drostanolone particularly valuable as an ancillary compound in cycles containing aromatizable steroids.

    The anabolic-to-androgenic ratio of drostanolone presents an interesting profile. Comparative assessments typically rate its anabolic activity at approximately 62 relative to testosterone (which scores 100), while its androgenic rating sits at roughly 25. This disparity suggests a compound that provides moderate anabolic benefits with disproportionately lower androgenic activity-though in practice, the androgenic effects on hair and prostate remain clinically significant for genetically predisposed individuals.

    A notable feature of drostanolone is its lack of 17-alpha alkylation. This structural characteristic means the compound is not associated with significant hepatotoxicity, unlike oral anabolic steroids such as oxymetholone or stanozolol. The liver metabolizes drostanolone through standard pathways before the compound is excreted primarily in urine, without the strain imposed by C17-alpha alkylated compounds.

    Drostanolone propionate functions as what practitioners often describe as a "cosmetic" or "polishing" compound rather than a primary mass-builder. Its most prominent applications center on the final stages of contest preparation, where the objective shifts from building tissue to revealing the underlying muscular structure.

    The compound's anti-estrogenic activity reduces subcutaneous water retention, which contributes to a drier, harder appearance. When body fat levels are already low-typically below 10-12%-this effect becomes visually pronounced, giving muscles a distinctly "etched" or "grainy" quality. This aesthetic outcome represents the primary reason physique athletes incorporate drostanolone during cutting phases.

    In stacking protocols, drostanolone frequently accompanies testosterone, serving multiple functions within the cycle architecture. It provides moderate anabolic support while simultaneously mitigating estrogenic side effects that might arise from the testosterone component. The compound also contributes to increased red blood cell production, which can enhance oxygen delivery to working muscles and support endurance during training.

    The 100mg/ml concentration offers practical advantages for dosing flexibility. Practitioners can adjust injection volume to fine-tune weekly dosages without being constrained by higher-concentration formulations that make small adjustments cumbersome. This concentration also aligns well with the compound's pharmacokinetic profile, allowing for straightforward dose calculations when administering injections every other day.

    Standard bodybuilding dosages for drostanolone propionate typically range from 300mg to 500mg per week. Lower doses in the 200-300mg weekly range are sometimes employed when the compound serves primarily as an ancillary anti-estrogenic agent rather than a primary anabolic driver. Higher doses exceeding 600mg weekly offer diminishing returns while amplifying side effect risks, particularly regarding lipid profile deterioration and androgenic effects on hair and prostate.

    The short propionate ester necessitates frequent administration to maintain stable blood levels. Every-other-day injection schedules are most common, though some practitioners prefer daily administration with smaller volumes for even greater stability. The 100mg/ml concentration makes every-other-day dosing straightforward: a 300mg weekly protocol translates to approximately 85mg per injection when administered every other day.

    Cycle duration for drostanolone propionate typically spans 6 to 8 weeks when used as a standalone or as part of a cutting stack. Shorter cycles are sometimes preferred because the compound's effects are primarily aesthetic and plateau relatively quickly. Extended use beyond 10-12 weeks offers little additional benefit while increasing cumulative exposure to cardiovascular and androgenic risks.

    The compound is rarely used as a solo cycle due to its moderate anabolic potency and HPTA suppression. Most commonly, it is stacked with a testosterone base at 150-300mg weekly, which provides the necessary anabolic foundation while drostanolone contributes its drying and hardening effects. This combination also helps maintain libido and overall hormonal balance during the cycle.

    The elimination half-life of drostanolone propionate following intramuscular injection is approximately 2 to 3 days. This relatively short window dictates the frequent injection schedule required for stable blood levels. The compound clears from the system within three to five days after the last injection.

    Detection time for anti-doping purposes extends considerably beyond the active half-life. Metabolites of drostanolone can be identified in urine for up to 24 days following intramuscular injection, with key biomarkers including S4 (2α-methyl-5α-androstan-17-one-6β-ol-3α-sulfate) and G1 (2α-methyl-5α-androstan-17-one-3α-glucuronide). Some sources suggest detection may extend to approximately two months in certain testing scenarios, making drostanolone a particularly risky choice for athletes subject to drug testing.

    The pharmacokinetic profile contrasts notably with drostanolone enanthate, the longer-ester variant. Enanthate has a half-life of approximately 5 to 7 days, permitting less frequent injections-typically once or twice weekly-but with slower onset of effects. The propionate ester provides faster onset and more rapid clearance, which some practitioners prefer for contest preparation where timing and precision matter most.

    Despite its reputation as a "mild" compound, drostanolone propionate does suppress the hypothalamic-pituitary-testicular axis (HPTA) at bodybuilding dosages. The suppression occurs primarily through androgen receptor activation in the hypothalamus and pituitary rather than through estrogenic feedback mechanisms, since drostanolone does not aromatize. This single-pathway suppression is typically less profound than that caused by aromatizing compounds, but it is nonetheless real and requires structured recovery.

    Blood work from practitioners following drostanolone cycles has documented testosterone levels below 100 ng/dL, indicating that significant HPTA suppression does occur even with this DHT-derived compound. The recovery protocol should therefore be treated with the same seriousness as recovery from any other suppressive cycle.

    Post-cycle therapy should commence approximately 3 to 5 days after the final drostanolone propionate injection, once the compound has cleared sufficiently from the system. Starting PCT too early-while drostanolone remains active-wastes the serm's effectiveness because the exogenous androgen will continue suppressing natural production.

    A standard PCT protocol for drostanolone cycles typically involves a combination of selective estrogen receptor modulators. Clomid (clomiphene citrate) is commonly administered at 50mg daily for the first two weeks, followed by 25mg daily for an additional two to four weeks. Nolvadex (tamoxifen citrate) is often included as well, dosed at 40mg daily initially and tapered to 20mg daily for the remainder of the protocol. This dual-serm approach addresses both the estrogen receptor blockade and the stimulation of gonadotropin release.

    The total PCT duration should span 4 to 6 weeks, with blood work performed at the midpoint and conclusion to assess recovery progress. Testosterone levels, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) should all be monitored to confirm that natural production is returning. Some practitioners extend PCT to 8 weeks if recovery appears sluggish, particularly following extended or high-dose cycles.

    The side effect profile of drostanolone propionate is dominated by androgenic rather than estrogenic concerns. The most common complaints among users relate to hair loss acceleration and prostate-related symptoms.

    For individuals with a genetic predisposition to male pattern baldness, drostanolone can rapidly accelerate hair follicle miniaturization. DHT-derived compounds deliver strong androgen receptor stimulation at the scalp, and because drostanolone is already a DHT derivative, 5-alpha reductase inhibitors such as finasteride offer limited protection. The enzyme that finasteride blocks is not required for drostanolone's androgenic activity, making the compound particularly hazardous for those concerned about hair retention.

    Prostate effects present another significant concern. DHT stimulation can contribute to benign prostatic hyperplasia, potentially causing urinary symptoms such as increased frequency, urgency, or difficulty initiating urination. Older users or those with existing prostate enlargement should exercise particular caution, as drostanolone may exacerbate these conditions.

    The cardiovascular impact of drostanolone warrants serious attention. The compound has been documented to promote an atherogenic lipid profile characterized by reduced HDL cholesterol and elevated LDL cholesterol. This shift in lipid parameters can accelerate arterial plaque formation over time, particularly with repeated or extended cycles. Regular blood work monitoring lipid values during and after cycles is strongly recommended.

    Unlike oral 17-alpha alkylated steroids, drostanolone propionate does not impose significant hepatotoxic stress. However, this relative hepatic safety does not negate the importance of monitoring liver function, particularly when drostanolone is stacked with other compounds that may carry hepatotoxic potential.

    Drostanolone is classified as a Schedule III controlled substance in the United States, placing it alongside other anabolic steroids with recognized medical applications but high potential for abuse. In the context of sport, it is explicitly prohibited by the World Anti-Doping Agency under category S1: Anabolic Agents. The prohibition applies both in-competition and out-of-competition, reflecting the compound's potential for performance enhancement.

     The detection window for drostanolone metabolites extends well beyond the active life of the compound. Athletes subject to random testing face significant risk, as metabolites can remain detectable for approximately 24 days after the last injection, with some reports extending this window to 29 days or longer. This extended detection profile makes drostanolone a particularly poor choice for tested athletes, even during off-season periods.

Brand	STROMUSC
Trade names	Drolban, Masteril, Masteron, Dromostanolone propionate; NSC-12198; Drostanolone 17β-propionate;
CAS	58-19-5
Molar mass	360.538
Formula	C23H36O3
Purity	Above 98%
Apprarance	100mg/ml, 10ml/bottle

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-15871669785

   

                                  

 

    Drostanolone propionate represents a specialized tool within the bodybuilding pharmacopeia, one whose value lies not in dramatic mass gains but in the refinement of an already-developed physique. Its inability to aromatize, combined with direct anti-estrogenic activity, positions it as a unique compound for creating the hard, dry, defined appearance that competitive physique athletes seek.

    The 100mg/ml concentration serves practical needs, offering dosing flexibility that aligns with the propionate ester's short half-life and the frequent injection schedule it necessitates. However, this convenience does not diminish the compound's capacity for significant side effects, particularly regarding hair loss, prostate health, and cardiovascular lipid parameters.

    Understanding drostanolone propionate requires acknowledging its dual nature: a pharmaceutical agent with legitimate historical medical applications, and a performance-enhancing compound with real risks that demand respect. The decision to use such a compound-like all decisions involving anabolic steroids-should be made with full awareness of the pharmacological realities, potential consequences, and legal implications involved.

Hot Tags: premium brand stromusc drostanolone propionate 100mg/ml for bodybuilding cas:58-19-5, China premium brand stromusc drostanolone propionate 100mg/ml for bodybuilding cas:58-19-5 manufacturers, suppliers, factory